

Remarks

In response to the Restriction Requirement mailed January 23, 2007 in connection with the above-identified patent application. Applicants elect for an affinity enhanced modified nucleoside a sugar modified nucleoside and for an affinity decreasing modified nucleoside a base modified nucleoside. Applicants further elect for the species of affinity enhancing sugar modified nucleoside a 2'-F modified nucleoside and for the species of affinity decreasing base modified nucleoside an inosine base modified nucleoside. All of the claims pending after entry of this amendment read on the elected species.

A listing of the claims has been included to clarify the election. Claims 1-11, 14, 15, 17-20, 23, 24, 26, 28-35, 38, 40 and 51-56 were pending in the present application. Claims 18, 20, 23, 26, 28, 29, 35 and 51-56 have been cancelled and claims 1-11, 15, 17, 19, 24, 30, 34, 38 and 40 have been amended herein, support for which can be found throughout the specification and claims. New claims 57-60 have been added herein, support for which can also be found throughout the specification and claims. No new matter has been added. Upon entry of the present amendment, claims 1-11, 14, 15, 17, 19, 24, 30-34, 38, 40, and 57-60 will be pending.

DOCKET NO.: CORE0005USA
Application No.: 10/561,618
Action Mailed: January 23, 2007

PATENT

Conclusion

Applicants believe that the foregoing constitutes a complete and full response to the official action of record. Accordingly, an early and favorable action is respectfully requested.

Respectfully submitted,

Robert S. Andrews

Date: April 20, 2007
Robert S. Andrews
Registration No. 44,508
Isis Pharmaceuticals, Inc.
1896 Rutherford Road
Carlsbad, CA 92008
Telephone: (760) 603-2352
Facsimile: (760) 603-3820